US court orders Eli Lilly to pay royalties on diabetes drugs

Eli Lilly is experiencing judicial headwind in the US, as a federal court has ordered the Novo Nordisk competitor to pay royalities from insulin sales to an Arizonan firm.

Photo: Mike Blake/Reuters/Ritzau Scanpix

Eli Lilly owes an Arizonan company royalties from insulin product sales, a US court has ruled, as reported by news organization Endpoint News. A trial is now likely.

The federal court in Arizona has reached the conclusion that Novo Nordisk-competitor Eli Lilly, which is based in the US, must pay royalities to the firm Research Corporation Technologies, which is headquartered in Tuscon, Arizona.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs